Cytori Therapeutics

About Us

Reconstructive Surgery - Breast Cancer Facts

• Breast cancer is a major public health problem¹. More than one million women worldwide are diagnosed with breast cancer annually, including more than 370,000 women in Europe² and more than 240,000 women in the United States³.

• One in eight American women⁴ who live to be 85 years of age and one in nine European women will develop or are diagnosed with breast cancer⁵.

• The incidence of breast cancer is increasing, particularly among younger women: 35 percent of women with breast cancer are under 55, and 12 percent are under 45. Breast cancer remains the main cause of death in women between ages 35 and 59⁶.

• Breast conserving therapy for early-stage breast cancer is an accepted treatment and an established alternative to mastectomy⁸. Of the newly diagnosed cancer cases, at least 3 of 4 breast cancer patients are eligible for breast conserving therapy⁷, which includes 278,000 women in Europe and 180,000 in the United States.

• Women with breast cancer currently have limited options for breast reconstruction, primarily consisting of either the insertion of an artificial implant or a tissue flap procedure.  Both are associated with potentially significant complications. Artificial implants can cause rupture, pain, capsular contracture (scar tissue formation around the implant), infection, or an unpleasing cosmetic result. Tissue flap procedures create permanent scarring at two surgical sites and may cause donor site complications, such as abdominal hernias and muscle damage or weakness, as well as breast asymmetry⁹.

• Cell-Enhanced Reconstruction represents a novel and natural treatment approach for post-treatment breast cancer patients. Adipose (body fat) is one of the body’s richest and most accessible sources of stem and regenerative cells10 that can be easily removed from an unwanted area(s) with liposuction, processed with the Celution™ System EU, prepared and reinserted for breast reconstruction in one surgical procedure.

1. 1 Schwartsmann, G. (2001). Breast Cancer in South America: Challenges to Improve Early Detection and Medical Management of a Public Health Problem. Journal of Clinical Oncology, (19), No 18S (September 15 Supplement), 118s-124s. Retrieved December 10, 2007, from http://jco.ascopubs.org/cgi/content/full/19/suppl_1/118s.



2. 2 Boyle P & Ferlay J. (2005). Cancer incidence and mortality in Europe, 2004. Annals of Oncology (16), 481-488.



3. 3 American Cancer Society. (2007). Breast Cancer Facts & Figures 2007-2008. Atlanta: American Cancer Society, Inc. Retrieved December 10, 2007, from http://www.cancer.org/downloads/STT/BCFF-Final.pdf.



4. 4 Y-ME National Breast Cancer Organization. Retrieved December 10, 2007, from http://www.y-me.org/information/breast_cancer_news/breast_cancer_statistics.php.



5. 5 The European Parliamentary Group on Breast Cancer and EUROPA DONNA. Retrieved December 10, 2007, from http://www.epgbc.org/BreastCancerFact.asp.



6. 6 The European Parliamentary Group on Breast Cancer and EUROPA DONNA. Retrieved December 10, 2007, from http://www.epgbc.org/BreastCancerFact.asp.



7. 7 Jacobson J.A. et al. (1995). Ten-Year Results of a Comparison of Conservation with Mastectomy in the Treatment of Stage I and II Breast Cancer. NEJM, (332), 907-911.

>
8. 8 American Cancer Society. (2007). Breast Reconstruction After Mastectomy. Retrieved December 10, 2007, http://www.cancer.org/docroot/CRI/content/CRI_2_6X_Breast_Reconstruction_After_Mastectomy_5.asp.


9. 9 Kern, S. et al. (2006). Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells; 24, 1294-1301.